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Aim To analyze the association of estrogen receptor α 
(ORα) gene polymorphisms with cytokine genes expres-
sion in patients with systemic lupus erythematosus (SLE) 
and controls.
Methods Genomic DNA was extracted and polymor-
phisms of XbaІ (XX, Xx, or xx genotype) and PvuII (PP, Pp, or 
pp) in intron 1 of ORα gene were detected by polymerase 
chain reaction-restriction fragment length polymorphisms 
(PCR-RFLP) method. The messenger RNA (mRNA) levels 
of interleukin (IL)-10, IL-4, interferon (IFN)-γ, and IL-2 were 
assessed by semiquantitative reverse transcription poly-
merase chain reaction (RT-PCR).
Results In patients with SLE with PpXx genotype, IL-10 and 
IL-4 mRNA expression was higher (P < 0.001 and P = 0.013, 
respectively), while in patients with SLE with Ppxx geno-
type IFN-γ and IL-2 mRNA expression was lower than in 
controls (P < 0.001). There was no significant difference in 
mRNA expression of 4 cytokines among controls with vari-
ous genotypes.
Conclusion ORα gene polymorphism may be associated 
with the expression of IL-10, IL-4, IL-2, and IFN-γ in patients 
with SLE.
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Systemic lupus erythematosus (SLE) is an autoimmune 
disease characterized by polyclonal B cell activation and 
overproduction of pathogenic autoantibodies (1,2). Al-
though etiopathology of SLE is not clearly understood, 
the mechanism seems to be affected by sex hormones. 
Epidemiologically, there is a female predominance in the 
number of diseased of about 90%. The peak incidence of 
SLE occurs in the reproductive period, whereas the onset 
of SLE in postmenopause, characterized by loss of estro-
gen production, is relatively uncommon (3).
Estrogen must combine with target tissue cytolymph 
or intranuclear estrogen receptor in order to produce a 
marked effect. However, estrogen receptor α (ORα) pro-
duces effects by binding to a specific estrogen response 
element, which is cis-acting enhancer located with-
in the regulatory regions of target genes. Human ORα 
gene, also named ESR1, is located on chromosome 6q25, 
which comprises 8 exons separated by 7 intronic regions 
and spans more than 140 kilobases (4,5). In intron 1, 
there are 2 polymorphism sites: the PvuII polymorphism, 
caused by a T/C transition and located approximately 0.4 
kb upstream of exon 2, and the XbaI polymorphism (XX, 
Xx, or xx genotype), located approximately 50 bp away 
from the PvuII polymorphism (PP, Pp, or pp genotype) 
site. Distribution of ORα gene polymorphism has been 
related to sex, disease onset age, and clinical symptoms 
(6-8). For example, unusual PvuII C and XbaI G alleles 
have been associated with a milder form of SLE, char-
acterized by skin manifestations, later onset, and less or-
gan damage (7). The frequency of the combined ppXx 
genotype was greater in patients with childhood onset 
SLE than in controls or patients with adult onset SLE (8). 
Correlation of ORα gene polymorphism with some defi-
nite clinical manifestation suggests that ORα gene poly-
morphism probably serve as a genetic background of 
SLE. In addition, it has been demonstrated that imbal-
ance between Th1 and Th2 cytokine production plays 
a key role in the induction and development of several 
autoimmune diseases. In patients with SLE, serum levels 
of Th2 cytokines, such as interleukin (IL)-4, IL-6, and IL-10, 
are elevated, while a decrease in production of Th1 cy-
tokines, including IL-2 and interferon (IFN)-γ, is observed 
(9-12). However, there have been no reports on the rela-
tionship between the ORα gene polymorphism and the 
cytokines expression in patients with SLE. So, we ana-
lyzed the relationship between PvuII and XbaI restric-
tion fragment length polymorphism (RFLP) of ORα and 




The present study included 378 women – 157 healthy con-
trols and 221 patients with SLE. patients with SLE were re-
cruited from the Department of Rheumatism, Shandong 
Provincial Hospital, whereas the controls were select-
ed from the staff members of Shandong University from 
March to December 2007. The inclusion criterion for pa-
tients with SLE was the fulfillment of at least 4 of Ameri-
can College of Rheumatology classification criteria (13,14). 
The age of patients was 27.6 ± 7.4 and that of controls was 
28.3 ± 5.4. All participants gave their informed consent be-
fore enrollment. The study was approved by the ethics 
committee of Shandong Provincial Hospital and the Shan-
dong University.
Estrogen receptor gene α polymorphism analysis
Genomic DNA was extracted from whole blood (EDTA 
treated) using the TIANamp blood DNA kit supplied by 
Tiangen (Beijing, China). To genotype the PvuII and XbaI 
restriction polymorphic sites in intron 1 of ORα gene, poly-
merase chain reaction (PCR) and specific oligonucleotide 
primers were used. The upstream primer sequence was 5’-
CTG CCA CCC TAT CTG TAT CTT TTCCTA TTC TCC-3’, and 
downstream primer sequence was 5’-TCT TTC TCT GCC 
ACC CTG GCG TCG ATT ATC TGA-3’. This pair of primers pre-
dicts a production of 1.3 kb (15). The reaction was carried 
out under the following conditions: at 95°C for 7 minutes, 
35 cycles at 94°C for 30 seconds, at 62°C for 40 seconds, at 
72°C for 90 seconds, and finally at 72°C for 10 minutes. Af-
ter amplification, the PCR products were digested with 10 
units PvuII or XbaI at 37°C for 7 hours and electrophoresed 
Figure 1.
the genotype of estrogen receptor α gene after Pvuii or Xbai digesting. 
1 – pp genotype; 2 – PP genotype; 3 – Pp genotype; 4 – xx genotype; 5 
– XX genotype; 6 – Xx genotype.
119Lu et al: Estrogen Receptor Gene α Polymorphisms and Cytokine Genes Expression in SLE
www.cmj.hr
in 1% ethidium bromide-agarose gel. PvuII digestion re-
sulted in genotypes PP (1.3kb), Pp (1.3kb, 850bp, 450bp), 
and pp (850bp, 450bp), while XbaI digestion resulted in 
genotypes XX (1.3kb), Xx (1.3kb, 910bp, 390bp), and xx 
(910bp, 390bp) (Figure 1).
total Rna extraction for molecular studies
Mononuclear cells were isolated from 5 mL fresh human pe-
ripheral blood with Lymphocytes Separation Medium (LSM, 
Krackeler Scientific, Albany, NY, USA). Total RNA from 5 × 106 
peripheral blood mononuclear cells (PBMC) was obtained 
from all patients by a procedure described elsewhere (16).
Synthesis of complementary dna (cdna)
Synthesis of cDNA was performed by heating total RNA 
from 5 × 106 PBMCs at 72°C for 10 minutes, cooling it on 
ice, and adjusting it to a total volume of 20 μL containing 
0.5 μmol dNTPs, 3 μg of random primers, 10 U RNase inhib-
itor, and 200 U M-MLV reverse transcriptase. Samples were 
incubated at 37.5°C for 60 minutes, heated to 95°C for 10 
minutes in order to inactivate traces of reverse transcrip-
tase activity, and stored at -20°C.
analysis of cytokine gene expression by semiquantitative 
PCR method
With cDNA as the template, PCR was carried out with prim-
ers for IL-10, IFN-γ, IL-4, IL-2, and β-actin (Table 1). The pro-
cedure conditions were pre-denaturation at 95°C for 7 
minutes; 35 cycles of denaturation at 94°C for 60 seconds, 
annealing at 64°C (IL-10), 52°C (IFN-γ), 60°C (IL-4), 60°C (IL-2) 
for 30 seconds, extension at 72°C for 60 seconds, and the 
final cycle of further 10 minutes at 72°C. Each cytokine was 
amplified with β-actin at the same time in order to detect 
the cytokine’s quantity by ratios of the cytokine and β-actin.
Statistical methods
Genotype frequencies were calculated. Results from the 
control and test groups were compared using the χ2 test 
or Fisher exact test for small samples. In each group, the 
observed distribution of homozygotes and heterozygotes 
was in agreement with the Hardy-Weiberg equilibrium. 
P > 0.05 indicated that the groups had the same genetic 
equilibrium and that the data were drawn from the same 
Mendelian population. Differences in cytokines expression 
data (mean ± standard deviation) among the various ORα 
genotypes were tested by Kruskal-Wallis test. Differences 
between patients with SLE and controls were determined 
by t test or Mann-Whitney test for the group of skewed 
distribution or heterogeneity of variance. P < 0.05 was con-
sidered statistically significant. SPSS statistical package, 
version 13.0 for Windows (SPSS Inc., Chicago, IL, USA) was 
used.
RESuLtS
distribution of oRα genotypes in patients with SLE
The distribution of genotypes in both patients and con-
trols was in agreement with the Hardy-Weinberg equilib-
rium (P > 0.05). There was no significant difference in the al-
lele frequency of PvuII or XbaI RFLPs between control and 
SLE group (Table 2). Genotypes ppXX and ppXx were not 
found in any participant and PpXX was not found in any 
taBLE 1. the primer sequence of interleukin-10, interferon-γ, interleukin-4, interleukin-2, and β-actin
Cytokine the primer sequence
Interleukin -10 5′-TTA CCT GGA GGA GGT GAT GC-3′ 5′-TGG GGG TTG AGG TAT CAG AG-3′
Interferon-γ 5′-GCA GAG CCA AAT TGT CTC CT-3′ 5′-ATG CTC TTC GAC CTC GAA AC-3′
Interleukin -4 5′-CTG CAA ATC GAC ACC TAT TA-3′ 5′-GAT CGT CTT TAG CCT TTC CA-3′
Interleukin -2 5′-TGC CAC AAT GTA CAG GAT GC-3′ 5′-GCC TTC TTG GGC ATG TAA AA-3′
β-actin 5′-CTC CAT CCT GGC CTC GCT GT-3′ 5′-GCT GTC ACC TTC ACC GTT CC-3′
taBLE 2. allele and genotype frequencies (no., %) of estrogen 
receptor α (oRα) polymorphism in controls and patients with 
systemic lupus erythematosus (SLE)
SLE (n = 221) Control (n = 157) P*
For Pvuii
Allele P 160 (36.2)  92 (29.3) 0.051
p 282 (63.8) 222 (70.7)
Genotype PP  34 (15.4)  18 (11.5) 0.153
Pp  92 (41.6)  56 (35.7)
pp  95 (43.0)  83 (52.9)
For Xbai
Allele X  93 (21.0)  52 (16.6) 0.134
x 349 (79.0) 262 (83.4)
Genotype XX  10 (4.5)   7 (4.5) 0.171
Xx  73 (33)  38 (24.2)
xx 138 (62.4) 112 (71.3)
*hardy-Weiberg equilibrium test.
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SLE patient. Ppxx, PpXx, and ppxx were found to be 3 major 
genotypes in patients with SLE and controls (Table 3).
PBMC cytokine mRna expression
The levels of IL-10 and IL-4 mRNA in patients with SLE was 
significantly higher than in controls (P < 0.001). There were 
no significant differences between the two groups in the 
level of IFN-γ and IL-2 mRNA (Figure 2 and Table 4).
the relationship between the oRα gene polymorphism 
and cytokines
The level of IL-10 and IL-4 mRNA in patients with SLE with 
PpXx genotype was much higher than in controls. The 
level of IFN-γ and IL-2 mRNA in patients with SLE with 
Ppxx genotype was lower than in controls (Table 5). Fur-
thermore, cytokine gene expression was significantly dif-
ferent in patients with SLE with different ORα genotypes 
(Kruskal-Wallis test) (Table 6). The level of IL-10 mRNA in 
patients with PpXx was higher than in patients with PPXX, 
PPXx, Ppxx, and ppxx genotype (P = 0.018, P < 0.001, 
P < 0.001, P < 0.001, respectively), while the level of IL-
4 mRNA in patients with PpXx genotype was high-
er than in patients with PPXX, Ppxx, and ppxx (P = 0.027, 
P = 0.030, P = 0.021, respectively). The level of IFN-γ mRNA 
in patients with Ppxx genotype was lower than in patients 
with PPXX, PPXx, PPxx, PpXx, and ppxx (P = 0.009, P = 0.010, 
P = 0.046, P = 0.003, P < 0.001, respectively), while the level 
of IL-2 mRNA in patients with Ppxx genotype was lower 
than in patients with PPXX, PPXx, PpXx, and ppxx (P = 0.035, 
P = 0.042, P = 0.001, P = 0.001, respectively, Mann-Whitney 
test).
diSCuSSion
Our study showed that ORα genotypes Ppxx, PpXx, and 
ppxx were 3 major genotypes both in patients with SLE 
and control participants. However, there was no signifi-
cant difference in the distribution of these 3 ORα geno-
types between patients and controls. We also found that 
the level of IL-10 and IL-4 mRNA in patients with SLE was 
significantly higher than in controls, while there was no 
significant difference in the level of IFN-γ and IL-2 mRNA 
between the groups. We further analyzed the association 
of the ORα gene polymorphisms with the Th1 and Th2 cy-
tokine expression. The level of IL-10 mRNA in patients with 
SLE with PpXx genotype was higher than in healthy con-
Figure 2.
the mRna expression of th1 (interferon-γ and interleukin-2) and th2 (in-
terleukin-10 and interleukin-4) cytokines. (A) interferon-γ; (B) interleu-
kin-10; (C) interleukin-2; (D) interleukin-4. Lane 1, 3, 5, 7 is the β-actin’s 
expression. Lane 2 and lane 4 shows systemic lupus erythematosus pa-
tients’ cytokine expression, whereas lane 6 and lane 8 show controls’ cy-
tokine expression.
taBLE 3. distribution of estrogen receptor α (oRα) genotypes 
in patients with systemic lupus erythematosus (SLE) and 
controls (no., %)
Genotype SLE controls P
PPXX 14 (6.3)  6 (3.8) 0.354
PPXx 22 (10.0)  9 (5.7) 0.183
PPxx  5 (2.3)  0 0.079†
PpXX  0  3 (1.9) 0.071†
PpXx 55 (24.9) 30 (19.1) 0.212
Ppxx 36 (16.3) 36 (22.9) 0.112
ppXX  0  0 NA
ppXx  0  0 NA
ppxx 89 (40.3) 73 (46.5) 0.247
*na –not applicable.
†Fisher exact test for small samples.
taBLE 4. Cytokine expression (relative expression to β-actin, 
mean ± standard deviation) in the peripheral blood mono-





Patients with SLE 
(n = 221)
Interleukin-10 0.24 ± 0.06 0.37 ± 0.21*
Interleukin-4 0.38 ± 0.12 0.43 ± 0.16*
Interferon-γ 0.39 ± 0.17 0.40 ± 0.18
Interleukin-2 0.31 ± 0.09 0.31 ± 0.10
*P < 0.01 by t test for independent samples comparing controls with 
patients with SLE.
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trols. There was also difference in IL-10 mRNA expression 
among patients with SLE with different ORα genotypes. In 
SLE group, the level of IL-10 mRNA in patients with PpXx 
genotype was significantly higher than in patients with 
PPXX, PPXx, Ppxx, and ppxx. IL-10 is a multifunctional cyto-
kine that plays a central role in the pathogenesis of SLE, in-
cluding regulation of growth and differentiation of B cells 
and auto-antibody production (17). Furthermore, the se-
rum level of IL-10 showed positive correlation with SLEDAI 
and anti-double stranded (ds)DNA and negative correla-
tion with C3, C4, and lymphopenia (18). The level of IL-4 
mRNA in patients with PpXx genotype was higher than in 
patients with PPXX, Ppxx, and ppxx genotypes. IL-4 and IL-
10 are predominantly produced by Th2 cells. An overpro-
duction of Th2 cytokines, which resulted in B-cell hyperac-
tivity, has been demonstrated in patients with SLE (19). Our 
results suggested that Th2 cytokines were predominant in 
patients with SLE with the PpXx genotypes.
The level of IFN-γ mRNA in patients with SLE with Ppxx 
genotype was much lower than in controls. In SLE group, 
the level of IFN-γ mRNA in patients with Ppxx genotype 
was lower than in patients with PPXX, PPXx, PPxx, PpXx, 
and ppxx genotypes, while the level of IL-2 mRNA in pa-
tients with Ppxx genotype was lower than in patients with 
PPXX, PPXx, PpXx, and ppxx genotypes. A previous study 
reported that patients with SLE disease activity index (SLE-
DAI)>10 had significantly fewer Th1 cells than controls or 
patients with SLEDAI<10, which suggested that the im-
balance of Th1/Th2-type cytokines in SLE mainly oc-
curred due to the decrease in Th1-type cells and may 
relate to lupus disease activity (20). Our results indi-
taBLE 5. Cytokine expression (relative expression to β-actin, mean ± standard deviation) and estrogen receptor α (oRα) gene poly-
morphisms in patients with systemic lupus erythematosus (SLE) and control
iL-10 iL-4 iFn-γ iL-2
Genotypes SLE controls P SLE controls P SLE controls P SLE controls P
PPXX 0.36 ± 0.18 0.23 ± 0.05 0.101 0.37 ± 0.14 0.35 ± 0.10 0.729 0.37 ± 0.13 0.38 ± 0.13 0.861 0.32 ± 0.09 0.31 ± 0.11 0.988
PPXx 0.26 ± 0.07 0.24 ± 0.05 0.393 0.45 ± 0.17 0.36 ± 0.08 0.165 0.36 ± 0.13 0.36 ± 0.07 0.958 0.29 ± 0.07 0.27 ± 0.08 0.654
PPxx 0.38 ± 0.22 NA NA 0.39 ± 0.04 NA NA 0.32 ± 0.01 NA NA 0.28 ± 0.04 NA NA
PpXX NA 0.25 ± 0.10 NA NA 0.27 ± 0.03 NA NA 0.35 ± 0.07 NA NA 0.37 ± 0.06 NA
PpXx 0.49 ± 0.23 0.27 ± 0.06 <0.001† 0.48 ± 0.16 0.39 ± 0.13 0.013‡ 0.38 ± 0.18 0.37 ± 0.08 0.012† 0.31 ± 0.09 0.30 ± 0.08 0.485
Ppxx 0.28 ± 0.06 0.26 ± 0.05 0.147 0.41 ± 0.12 0.37 ± 0.12 0.214 0.27 ± 0.11 0.41 ± 0.05 <0.001† 0.25 ± 0.05 0.33 ± 0.12 <0.001†
ppxx 0.27 ± 0.10 0.25 ± 0.06 0.512 0.43 ± 0.17 0.38 ± 0.13 0.097 0.47 ± 0.26 0.41 ± 0.10 0.410 0.34 ± 0.13 0.31 ± 0.08 0.702
*na – not applicable.
†Mann-Whitney test.
‡t test.
taBLE 6. Statistical significance of cytokine expression between patients with different genotypes in systemic lupus erythematosus
P (Mann-Whitney test)
Genotypes interleukin-10 interleukin-4 interleukin-2 interferon-γ
PPXX & PPXx 0.061 0.150 0.597 0.987
PPXX & PPxx 0.823 0.823 0.754 1.000
PPXX & PpXx 0.018 0.027 1.000 0.858
PPXX & Ppxx 0.072 0.331 0.035 0.009
PPXX & ppxx 0.350 0.296 0.736 0.256
PPXx & PPxx 0.146 0.650 0.880 0.786
PPXx & PpXx <0.001 0.321 0.554 0.627
PPXx & Ppxx 0.335 0.409 0.042 0.010
PPXx & ppxx 0.110 0.482 0.325 0.206
PPxx & PpXx 0.259 0.237 0.567 0.482
PPxx & Ppxx 0.301 0.954 0.301 0.046
PPxx & ppxx 0.277 0.811 0.522 0.358
PpXx & Ppxx <0.001 0.030 0.001 0.003
PpXx & ppxx <0.001 0.021 0.639 0.065
Ppxx & ppxx 0.091 0.861 0.001 <0.001
CLINICAL SCIENCE122 Croat Med J. 2009; 50: 117-23
www.cmj.hr
cate that Th2 cytokines were predominant in patients with 
SLE with the Ppxx genotype, which resulted from the de-
crease in Th1 cytokines. These conflicting findings might 
be attributed to differences between the studies in the 
stage of the disease and timing of treatment. Tokano et al 
(21) reported that the concentration of IFN-γ (determined 
using the sandwich ELISA kit) was increased in the serum 
in the active stage of SLE. However, Chen et al (20) report-
ed that patients with SLE disease activity index (SLEDAI>10 
had significantly fewer CD4+ or CD8+ T cells producing IFN-
γ (determined by flow-cytometry following whole-blood 
culture) than patients with SLEDAI = 0, SLEDAI between 1 
and 10, or healthy controls. In our study, the patients were 
all in the active stage of SLE with SLEDAI>10.
Since the validity of these findings may be compromised 
by the relatively limited size of our patient group, molec-
ular mechanism by which the ORα gene polymorphisms 
influence the Th1/Th2 cytokine expression need to be ex-
plored in future studies, which would include more par-
ticipants.
SLE is a multifactorial autoimmune disease with pathogen-
esis influenced by genetic factors. Polymorphisms occur 
frequently throughout the human genome and in some 
cases are known to alter either the expression or the func-
tion of a gene product (22). The association of ORα gene 
polymorphisms with breast cancer, hypertension, osteo-
porosis, and osteoarthritis has been reported in recent 
studies (23-27). The association of genetic polymorphism, 
which may alter the Th1/Th2 balance, with susceptibility 
to SLE has been previously reported (28). Our study con-
firmed this by showing that the ORα gene polymorphisms 
could influence the expression of IL-10, IL-4, IL-2, and IFN-γ 
in SLE. Our result indicates that the Th2 cell was predomi-
nant in patients with SLE with PpXx and Ppxx genotypes. 
Since SLE is a heterogeneous disease and its pathologic 
mechanisms are difficult to understand, it is important to 
bear in mind that it may be closely related to ORα gene 
polymorphisms.
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